University of Sussex
Browse
ADVMS_147 gf.pdf (1.05 MB)

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Download (1.05 MB)
journal contribution
posted on 2023-06-09, 01:27 authored by Mohsen Mazidi, Ehsan Karimi, Peyman Rezaie, Gordon FernsGordon Ferns
Aim: To undertake a systematic review and meta-analysis of randomized controlled trials of the effect of Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) therapy on serum C-reactive protein (CRP) concentrations. Method: PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched for the period up until March 16 2016. Prospective studies evaluating the impact of GLP-1 RAs on serum CRP were identified. A random effects model (using the DerSimonian-Laird method) and generic inverse variance methods were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. Heterogeneity was quantitatively assessed using the I2 index. Random effects meta-regression was performed using unrestricted maximum likelihood method to evaluate the impact of potential moderator. International Prospective Register for Systematic Reviews (PROSPERO) number CRD42016036868. Results: Meta-analysis of the data from 7 treatment arms revealed a significant reduction in serum CRP concentrations following treatment with GLP-1 RAs (WMD –2.14 (mg/dL), 95% CI -3.51, –0.78, P=0.002; I2 96.1%). Removal of one study in the meta-analysis did not change the result in the sensitivity analysis (WMD –2.14(mg/dL), 95% CI -3.51, –0.78, P=0.002; I2 96.1%), indicating that our results could not be solely attributed to the effect of a single study. Random effects meta-regression was performed to evaluate the impact of potential moderator on the estimated effect size. Changes in serum CRP concentration were associated with the duration of treatment (slope –0.097, 95% CI –0.158, -0.042, P<0.001). Conclusions: This meta-analysis suggests that GLP-1 RAs therapy causes a significant reduction in CRP.

History

Publication status

  • Published

File Version

  • Accepted version

Journal

Journal of Diabetes and its Complications

ISSN

1056-8727

Publisher

Elsevier

Issue

7

Volume

31

Page range

1237-1242

Department affiliated with

  • Division of Medical Education Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2016-06-02

First Open Access (FOA) Date

2017-05-31

First Compliant Deposit (FCD) Date

2016-06-02

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC